Englander Institute for Precision Medicine
Photo credit: EIPM

Dear Members of the Englander Institute,

I hope you’re enjoying the summer and continuing to stay healthy. We are closely monitoring the rise of the Delta variant, and encourage everyone to get vaccinated and to follow the new requirements from Dean Choi about wearing your mask on campus.

I’m very proud of our work over the past month, including the impressive news media coverage we generated, the events we participated in, the awards and grants we earned, and the research...

Graphic image credit Journal of Clinical Oncology

A new treatment for advanced urothelial cancer was effective with tolerable side effects in an international, multi-center phase 2 clinical trial led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.

The trial results prompted a U.S. Food and Drug Administration (FDA) accelerated approval of the treatment on April 13, giving patients with this very aggressive type of cancer a new therapeutic option.

In the ...

Photo credit: Nature Communications

A powerful immune-suppressing molecule produced by the body may hold the key to better treatments for autoimmune and inflammatory diseases, as well as for some cancers, according to a study by researchers at Weill Cornell Medicine and the University of Perugia.

In the study, published...